Mobile Menu
Contact
Search
Search Keyword
Our Company
Leadership Team
Careers
Grants & Sponsorships
Expanded Access
Contact Us
Programs & Pipeline
Programs
Pipeline
Resources
For Patients & Providers
Mitochondria & Disease
Mitochondrial Diseases
Community
Contact Us
Scientific Data
Publications
Presentations
Investors & News
About
Stock Information
Reports & Filings
News
Publications
IR Presentations
Events
Corporate Governance
Contact Us
Reports
Email Alerts
Contact Us
Investors & News
Latest News
June 27,2022
Stealth BioTherapeutics Corp Announces Receipt of Preliminary Non-Binding Proposal
June 14,2022
Stealth BioTherapeutics Granted Pre-NDA Meeting for Elamipretide as a Potential Treatment for Barth Syndrome
All News
Stock Quote (MITO)
Share
Why invest?
Our Company
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging.
Our Programs
We are investigating our lead product candidate in late stage clinical studies in three primary mitochondrial diseases – primary mitochondrial myopathy, Barth syndrome and Leber’s hereditary optic neuropathy – as well as an earlier stage clinical study in dry age-related macular degeneration.
Our Pipeline
We continue to expand our broad knowledge of mitochondrial biology and novel chemistries, and advance our mitochondrial platform of late-stage clinical programs and pipeline candidates.
Latest Reports
June 27, 2022
Form 6-K : Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16
HTML
June 27, 2022
Form SC 13D/A : Amended Statement of Beneficial Ownership
HTML
Reports
Latest Presentations
February 08, 2022
February Presentation - February 2022
Download
November 11, 2021
Third Quarter 2021 Financial Results Earnings Call
Download
Presentations
Events
May 02, 2022
ReCLAIM-2 Data Conference Call
Calendar
Webcast
March 28, 2022
Maxim Group 2022 Virtual Growth Conference
Calendar
Webcast
Financial Calendar
Media Relations
media@stealthbt.com
Investor Inquiries
Kendall IR
Adam Bero
abero@kendallir.com
Scroll to Top
